ZEALAND PHARMA AS
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1998-01-01
- Employees
- 150
- Market Cap
- $9.1B
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT03735225
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 106
- Registration Number
- NCT03690206
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇫🇷Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
- Conditions
- HypoglycemiaDiabetes Mellitus, Type 1
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 45
- Registration Number
- NCT03688711
- Locations
- 🇺🇸
Rainier Clinical Research, Inc., Renton, Washington, United States
🇺🇸AMCR Institute, Escondido, California, United States
🇺🇸ProSciento, Inc., Chula Vista, California, United States
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
- Conditions
- Hypoglycemia
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 42
- Registration Number
- NCT03667053
- Locations
- 🇺🇸
AMCR Institute, Inc, Escondido, California, United States
🇺🇸Indiana University, Department of Pediatrics, Indianapolis, Indiana, United States
🇩🇪Auf der Bult - Diabetes Center for Children, Hannover, Germany
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
- Conditions
- HypoglycemiaDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT03378635
- Locations
- 🇦🇹
Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇩🇪Profil, Neuss, Germany
🇺🇸ProSciento, Chula Vista, California, United States
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 75
- Registration Number
- NCT03279302
- Locations
- 🇺🇸
Covance CRU, Dallas, Texas, United States
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
- Conditions
- HypoglycemiaDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 112
- Registration Number
- NCT03216226
- Locations
- 🇨🇦
LMC Calgary, Calgary, Canada
🇦🇹CRC - Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇩🇪Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin, Hamburg, Germany
Feasibility Trial Testing the Bionic Pancreas With ZP4207
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: ZP4207 (dasiglucagon)Device: iPhone-based bionic pancreasDevice: iLet-based bionic pancreas
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02971228
- Locations
- 🇺🇸
MGH Diabetes Center, Boston, Massachusetts, United States
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 38
- Registration Number
- NCT02916251
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
A Phase 2 Trial Testing ZP1848 in Patients With SBS
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT02690025
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark